Publication :
Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells

bul.description.provenancenag spbfr
bul.rights.dateAccepPubl2004-07-23fr
bul.rights.periodeEmbargoforeverfr
bul.rights.raisonEmbargoInfiniPour que le document soit diffusé en libre accès, en accord avec le délai prescrit par l’éditeur de Cancer Biology and Therapy, il faudrait déposer la version acceptée pour publication, incluant toutes les modifications demandées, mais sans la mise en page de la revue. Pour ce faire, effectuez une demande de modification à l’aide de la liste des dépôts diffusés à partir du tableau de suivi.fr
bul.rights.typeDatedatePublicationfr
dc.contributor.authorRoussel, Élise
dc.contributor.authorCouët, Jacques
dc.contributor.authorBélanger, Martin
dc.contributor.authorGaudreau, Martin.
dc.date.accessioned2017-11-14T20:43:33Z
dc.date.available9999-12-31
dc.date.issued2004-07-23
dc.description.abstractCaveolin 1 expression is downregulated in various cancer cell lines. Interestingly, in several drug-resistant cancer cells, a strong induction of caveolin 1 expression has been reported suggesting a role for caveolin 1 in the acquisition and/or the maintenance of multidrug resistance phenotype. In addition, it was reported that p-glycoprotein localized to caveolin-rich membrane domains in these cells. In this study, we progressively exposed A549 lung adenocarcinoma cells to increasing doses of etoposide. Both R1 and R2 cell lines had greatly increased levels of p-glycoprotein expression while mrp expression levels were moderately increased but only R2 cells had raised caveolin levels compared to control A549 cells. Both caveolin-1 and p-glycoprotein colocalize in Triton-insoluble membrane domains in all our cell lines but only caveolins-1 was solubilized by the addition of octylglucoside at 4C suggesting that these two proteins are located in different membrane domains. Using an anti-caveolin-1 antibody, we did not succeed to immunoprecipitate p-glycoprotein. Interestingly, total cellular cholesterol (the major lipid component of caveolae and triton-insoluble domains) was greatly increased in both R1 and R2 cell lines compared to naive A549 cells.fr
dc.identifier.doi10.4161/cbt.3.10.1112fr
dc.identifier.issn1538-4047fr
dc.identifier.pubmed15326378fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/15846
dc.languageengfr
dc.publisherTaylor & Francisfr
dc.rightshttp://purl.org/coar/access_right/c_16ec
dc.subjectcaveolinfr
dc.subjectcaveolaefr
dc.subjectCytotoxic drugsfr
dc.subjectMultidrug resistancefr
dc.subject.rvmCavéolinesfr
dc.subject.rvmCavéolesfr
dc.subject.rvmPoumons -- Cancerfr
dc.subject.rvmCellules cancéreuses -- Résistance aux médicamentsfr
dc.subject.rvmÉtoposidefr
dc.titleRole of caveolin-1 in etoposide resistance development in A549 lung cancer cellsfr
dc.typearticle de recherche
dc.type.legacyCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationCancer Biology and Therapy, Vol 3 (10), 954-959 (2004)fr
dspace.accessstatus.time2023-03-28 18:00:31
dspace.entity.typePublication
relation.isAuthorOfPublication225aedeb-6830-4473-b07e-32b711352293
relation.isAuthorOfPublication4021daff-774e-4d6a-8b5a-958ed3f8c836
relation.isAuthorOfPublicationcfcaeb58-a5c5-460b-ab7f-3cbeecfb6aa3
relation.isAuthorOfPublicatione7527619-e4d7-4261-ae67-44fd52984d66
relation.isAuthorOfPublication.latestForDiscovery225aedeb-6830-4473-b07e-32b711352293
relation.isResourceTypeOfPublication4c433ef5-3937-4530-8252-cca17d715747
relation.isResourceTypeOfPublication.latestForDiscovery4c433ef5-3937-4530-8252-cca17d715747
rioxxterms.projectMT-14341fr
rioxxterms.project.funder-nameCanadian Institutes of Health Researchfr
rioxxterms.versionVoRfr
rioxxterms.version-of-recordhttp://dx.doi.org/10.4161/cbt.3.10.1112fr
Fichiers
Bundle original
Voici les éléments 1 - 1 sur 1
En cours de chargement...
Vignette d'image
Nom :
belanger3-10.pdf
Taille :
659.45 KB
Format :
Adobe Portable Document Format
Description :